AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein

Blood

Volumn 96, Issue 12, 2000, Pages 3939-3947

  Melnick, A ^a   Carlile, G W ^a   McConnell, M J ^a   Polinger, A ^a   Hiebert, S W ^a   Licht, J D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AML 1 ETO PROTEIN; CYCLIN A; HYBRID PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING SITE; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0034548852     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3939     Document Type: Article

References (53)

1. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
2. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis
3. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
4. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
5. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors
6. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
7. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: Implications for the pathogenesis of t(8;21)-positive leukemias
8. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1
9. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation
10. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter
11. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B
12. The t(8;21) fusion protein interferes with AML-1 B-dependent transcriptional activation
13. Functional domains of the t(8;21) fusion protein, AML-1/ETO
14. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein
15. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
16. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
17. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia
18. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors
19. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
20. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors
21. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein
22. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
23. Role of the histone deacetylase complex in acute promyelocytic leukaemia
24. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
25. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A
26. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis
27. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia
28. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
29. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein
30. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia
31. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression
32. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells
33. The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase
34. Targeting of the YY1 transcription factor to the nucleolus and the nuclear matrix in situ: The C-terminus is a principal determinant for nuclear trafficking
35. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia
36. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins
37. In depth mutational analysis of the PLZF BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions
38. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies
39. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
40. Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1
41. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis
42. The AML1/ETO fusion protein activates transcription of BCL-2
43. Intranuclear targeting of AML/CBFα regulatory factors to nuclear matrix-associated transcriptional domains
44. The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFα2 transcription factor
45. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: A potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing
46. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF
47. Identification and gene structure of a novel human PLZF-related transcription factor gene, TZFP
48. ROG, repressor of GATA, regulates the expression of cytokine genes
49. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene
50. + hematopoietic progenitors: Implications for t(8;21) leukemogenesis and monitoring residual disease
51. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling
52. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
53. Distinct interactions of PML-RARα and PLZF-RARα with corepressors determine differential responses to RA in APL